Lv1
80 积分 2026-01-09 加入
Repurposing of clinical-stage FLT3 inhibitor HYML-122 as a potent RIPK2 inhibitor for the treatment of inflammatory bowel disease
2个月前
已完结
Serum Extracellular Matrix Molecules and Their Fragments as Biomarkers of Inflammation and Fibrosis in Inflammatory Bowel Diseases: A Systematic Review
3个月前
已完结
Preclinical Translational Physiologically Based Pharmacokinetic Modeling for Predicting Human Pharmacokinetics of PROTACs: Case Studies of Vepdegestrant (ARV-471) and Bavdegalutamide (ARV-110)
5个月前
已完结
Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation
6个月前
已完结
Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn’s Disease and Ulcerative Colitis
6个月前
已完结
皖公网安备34019202002308
